Abstract
Purpose: To evaluate the efficacy and safety of trimethoprim/sulfamethoxazole and azithromycin combination for the treatment of ocular toxoplasmosis. Methods: Nineteen ocular toxoplasmosis patients treated with trimethoprim/sulfamethoxazole and azithromycin ± corticosteroid combination were retrospectively reviewed. Demographic data, clinical findings, the time interval until resolution of inflammation, recurrences, and drug side effects were collected. Results: The mean follow-up time of the patients was 25.0 ± 22.5 (range; 6 –66) months. Final visual acuity improved with a mean of 6 ± 4 lines in 15 patients (78.9%). Inflammatory findings began to subside within 14.8 ± 10.0 days. Three patients (15.8%) had recurrent attack. Only 1 patient (5.3%) had side effects from therapy. Conclusions: Trimethoprim/sulfamethoxazole and azithromycin combination is an effective and safe treatment modality for the treatment of ocular toxoplasmosis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
